EWA
CRSP icon

EverSource Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

EverSource Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.04M Buy
110,689
+21,006
+23% +$1.11M 0.2% 103
2026
Q1 		$4.27M Buy
89,683
+32,218
+56% +$1.7M 0.13% 132
2025
Q4 		$3.01M Sell
57,465
-39,969
-41% -$2.39M 0.11% 152
2025
Q3 		$6.31M Buy
97,434
+4,491
+5% +$258K 0.25% 85
2025
Q2 		$4.52M Buy
92,943
+8,063
+9% +$312K 0.2% 102
2025
Q1 		$2.89M Buy
84,880
+84,708
+49,249% +$3.59M 0.16% 119
2024
Q4 		$6.77K Sell
172
-1,308
-88% -$61.8K ﹤0.01% 2198
2024
Q3 		$69.5K Sell
1,480
-1,092
-42% -$55.4K ﹤0.01% 926
2024
Q2 		$147K Buy
2,572
+710
+38% +$41.1K 0.01% 668
2024
Q1 		$98.7K Buy
1,862
+446
+31% +$31.9K 0.01% 715
2023
Q4 		$88.6K Buy
1,416
+366
+35% +$20.2K 0.01% 684
2023
Q3 		$47.7K Buy
1,050
+82
+8% +$4.24K 0.01% 824
2023
Q2 		$54.3K Buy
968
+915
+1,726% +$51.9K 0.01% 803
2023
Q1 		$2.4K Buy
53
+28
+112% +$1.36K ﹤0.01% 1884
2022
Q4 		$1.02K Sell
25
-356
-93% -$18.9K ﹤0.01% 2084
2022
Q3 		$25K Buy
381
+366
+2,440% +$26.5K 0.01% 827
2022
Q2 		$1K Buy
+15
New +$882 ﹤0.01% 1622
2022
Q1 		– Sell
-34
Closed -$3K – 1731
2021
Q4 		$3K Buy
+34
New +$2.97K ﹤0.01% 1405

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EverSource Wealth Advisors's CRSP Position: Q2 2026 in Review

EverSource Wealth Advisors increased its CRISPR Therapeutics (CRSP) stake by 23% in Q2 2026, buying an estimated $1.11M and bringing the position to 110,689 shares worth $6.04M. The position accounts for 0.2% of the portfolio, ranked #103.

EverSource Wealth Advisors first reported a position in CRSP in Q4 2021 and has held it in 18 quarters since. The position peaked at $6.31M in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • EverSource Wealth Advisors held 110,689 shares of CRISPR Therapeutics worth $6.04M as of Q2 2026.
  • EverSource Wealth Advisors bought 21,006 CRISPR Therapeutics shares in Q2 2026, an estimated $1.11M.
  • CRISPR Therapeutics made up 0.2% of EverSource Wealth Advisors's portfolio in Q2 2026, its #103 holding.
  • EverSource Wealth Advisors first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • EverSource Wealth Advisors's CRISPR Therapeutics position peaked at $6.31M in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.